Showing results (101-110 of 142) with videos related to

Sort By:
Pageof 15
Clinical Pharmacokinetics|October 7, 2017
Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple MyelomaXiaoyu Yan, Pamela L Clemens, Thomas Puchalski, et al.
Cancer|July 27, 2021
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 studySagar Lonial, Hans C Lee, Ashraf Badros, et al.
British Journal of Haematology|February 26, 2013
A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myelomaPeter M Voorhees, Robert F Manges, Pieter Sonneveld, et al.
Blood|May 25, 2016
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myelomaSaad Z Usmani, Brendan M Weiss, Torben Plesner, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 28, 2018
Peripheral Immunotype Correlates with Minimal Residual Disease Status and Is Modulated by Immunomodulatory Drugs in Multiple MyelomaManisha Bhutani, David Foureau, Qing Zhang, et al.
The Lancet. Haematology|May 30, 2020
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trialsSaad Z Usmani, Hareth Nahi, Torben Plesner, et al.
The Lancet. Oncology|September 21, 2016
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trialAndrew J Yee, William I Bensinger, Jeffrey G Supko, et al.
British Journal of Haematology|March 20, 2024
Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN studyAjay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, et al.
Blood Advances|November 22, 2024
MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myelomaManisha Bhutani, Myra Robinson, David Foureau, et al.
Blood Advances|February 20, 2026
Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myelomaShebli Atrash, James Symanowski, Myra Robinson, et al.
Pageof 15